Real-world data in lupus nephritis: results from a European survey on renal function testing and burden of disease progression
Our study revealed lower-than-expected nephrologist-reported use of renal function testing to support diagnosis/monitoring of patients with LN in real-world clinical settings in Europe. Lower quality of life (QoL) was observed in patients with more progressed disease. Increased use of renal function testing is needed so that all LN patients are monitored closely to manage disease progression and avoid the associated QoL impact.
Authors
- Alice Eberhardt
- Francesco Pesce (ORCID: https://orcid.org/0000-0002-2882-4226)
- Liane Gillespie–Akar (ORCID: https://orcid.org/0000-0002-5737-7592)
- Beatriz Asin
- D. Clamp
- Emily J. Goddard (ORCID: https://orcid.org/0000-0002-1480-040X)
- Ancilla W. Fernandes
Institutions
- Pharmaceutical Product Development (United States) (US)
- Otsuka (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- Fatebenefratelli Hospital (IT)
- Otsuka Pharmaceutical (Spain) (ES)
- Azienda Ospedaliera Fatebenefratelli e Oftalmico (IT)
- Otsuka (United Kingdom) (GB)
- Otsuka (Germany) (DE)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1080/03007995.2024.2425387
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00